Allogene Therapeutics, Inc.
ALLO$614M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSOUTH SAN FRANCISCO226 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ALLO News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Fludarabine
Large B-cell Lymphoma
ALLO-647
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine | Phase 2 | Large B-cell Lymphoma | - | - |
ALLO-647 | Phase 2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply